Tyra Biosciences to Present at Upcoming Investor Conferences
Get Alerts TYRA Hot Sheet
Join SI Premium – FREE
- TD Cowen's 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA,
May 28-29, 2024 : Todd Harris, CEO of TYRA, will participate in a fireside chat onTuesday, May 28, 2024 , at1:00 pm ET . - Jefferies Global Healthcare Conference, June 5-6, 2024: TYRA management will participate in one-on-one meetings with investors during the conference.
- 45th Annual Goldman Sachs Global Healthcare Conference,
June 10-13, 2024 :Todd Harris , CEO of TYRA, will present onWednesday, June 12, 2024 , at8:40 am ET . TYRA management will also participate in one-on-one meetings with investors during the conference.
A live and archived webcast of the presentations will be available via the For Investors page on the Investor section of the TYRA website.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in
For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.
Contact:
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-present-at-upcoming-investor-conferences-302154687.html
SOURCE Tyra Biosciences
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Harel Insurance Investments and Financial Services reports record second quarter 2026 results; comprehensive income up 30% to NIS 1.024 billion, ROE 37%
- Consumer Trust in AI Is on Track to Grow by 15 Percentage Points by 2030
- JOYY Reports Second Quarter 2026 Financial Results: Total Revenues Increase to US$590.8 Million, Driven by Growth Across Core Businesses
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Goldman Sachs, Jefferies & Co, Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share